VRTX · News · 20261001N

Acquisition / Partnership / Divestiture

VERTEX PHARMACEUTICALS INC / MA · 2026-10-01 · Importance 71 · Surprise 60 · In source text

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for an estimated $8.8 billion, with the transaction described in the headline as a roughly $10 billion deal. The acquisition was one of the largest biotechnology transactions of 2026 and expands Vertex into specialty endocrinology beyond its core cystic fibrosis business. The deal was announced amid a third-quarter 2026 slowdown in biotechnology M&A, with just under $30 billion committed across 22 transactions.

Key facts

• Vertex Pharmaceuticals made one of the year's largest deals by acquiring Crinetics Pharmaceuticals for an estimated $8.8 billion. source
• Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals expands Vertex into specialty endocrinology. source
• TradingKey reported the stock drop was attributed in part to investor scrutiny over Vertex's recent acquisition of Crinetics Pharmaceuticals. source
• Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day. source
• Vertex Pharmaceuticals Inc. (VRTX) saw its stock price drop by 3.21% on Oct 1. source
• Fool.com reported that Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy. source

Impact estimates